Physician profile
Robert L Smith
NPI 1669583779
$1,321.22
in general payments reported to CMS, 2019-2025
15 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.01 · 2020: $92.12 · 2021: $54.93 · 2022: $129 · 2023: $456 · 2024: $320 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $316.42 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $255.47 | 2019-2022 | |
| Lilly USA, LLC | $252.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $111.62 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $70.63 | 2023-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $62.21 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $56.96 | 2023-2024 | Qulipta, Ubrelvy |
| Exact Sciences Corporation | $32.32 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $31.99 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $30.11 | 2023-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.34 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.62 | 2023 | |
| Eisai INC. | $20.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2024 | |
| Astellas Pharma US INC | $14.89 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.